CN120078760A - 治疗患有非小细胞肺癌的女性非吸烟者的方法 - Google Patents
治疗患有非小细胞肺癌的女性非吸烟者的方法 Download PDFInfo
- Publication number
- CN120078760A CN120078760A CN202510278250.XA CN202510278250A CN120078760A CN 120078760 A CN120078760 A CN 120078760A CN 202510278250 A CN202510278250 A CN 202510278250A CN 120078760 A CN120078760 A CN 120078760A
- Authority
- CN
- China
- Prior art keywords
- lung cancer
- small cell
- patient
- cell lung
- dithiobis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815762P | 2019-03-08 | 2019-03-08 | |
| US62/815,762 | 2019-03-08 | ||
| PCT/US2020/021615 WO2020185640A1 (en) | 2019-03-08 | 2020-03-08 | Method for treating female non-smokers with non-small cell lung cancer |
| CN202080034238.XA CN113906010A (zh) | 2019-03-08 | 2020-03-08 | 治疗患有非小细胞肺癌的女性非吸烟者的方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080034238.XA Division CN113906010A (zh) | 2019-03-08 | 2020-03-08 | 治疗患有非小细胞肺癌的女性非吸烟者的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120078760A true CN120078760A (zh) | 2025-06-03 |
Family
ID=72427123
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510278250.XA Pending CN120078760A (zh) | 2019-03-08 | 2020-03-08 | 治疗患有非小细胞肺癌的女性非吸烟者的方法 |
| CN202080034238.XA Pending CN113906010A (zh) | 2019-03-08 | 2020-03-08 | 治疗患有非小细胞肺癌的女性非吸烟者的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080034238.XA Pending CN113906010A (zh) | 2019-03-08 | 2020-03-08 | 治疗患有非小细胞肺癌的女性非吸烟者的方法 |
Country Status (11)
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2249825T3 (en) * | 2008-03-14 | 2016-01-11 | Bionumerik Pharmaceuticals Inc | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| ES2476602T3 (es) * | 2008-03-14 | 2014-07-15 | Bionumerik Pharmaceuticals, Inc. | Composiciones y métodos quimioprotectores |
| WO2009113989A1 (en) * | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
| US20170007561A1 (en) * | 2014-08-08 | 2017-01-12 | Bionumerik Pharmaceuticals, Inc. | Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur-containing, amino acid-specific small molecules |
-
2020
- 2020-03-08 SG SG11202109705Y patent/SG11202109705YA/en unknown
- 2020-03-08 MX MX2021010745A patent/MX2021010745A/es unknown
- 2020-03-08 KR KR1020217031523A patent/KR20220047208A/ko not_active Ceased
- 2020-03-08 JP JP2021553070A patent/JP2022525040A/ja active Pending
- 2020-03-08 CN CN202510278250.XA patent/CN120078760A/zh active Pending
- 2020-03-08 EP EP20770472.7A patent/EP3935043A4/en active Pending
- 2020-03-08 AU AU2020235823A patent/AU2020235823A1/en not_active Abandoned
- 2020-03-08 CA CA3132827A patent/CA3132827A1/en active Pending
- 2020-03-08 CN CN202080034238.XA patent/CN113906010A/zh active Pending
- 2020-03-08 WO PCT/US2020/021615 patent/WO2020185640A1/en not_active Ceased
- 2020-03-08 BR BR112021017716A patent/BR112021017716A2/pt unknown
-
2021
- 2021-09-08 US US17/469,765 patent/US20220168258A1/en not_active Abandoned
-
2025
- 2025-01-27 JP JP2025011556A patent/JP2025081338A/ja active Pending
- 2025-11-12 AU AU2025267367A patent/AU2025267367A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3935043A4 (en) | 2023-01-11 |
| EP3935043A1 (en) | 2022-01-12 |
| BR112021017716A2 (pt) | 2021-11-16 |
| AU2020235823A1 (en) | 2021-11-04 |
| SG11202109705YA (en) | 2021-10-28 |
| KR20220047208A (ko) | 2022-04-15 |
| JP2022525040A (ja) | 2022-05-11 |
| CN113906010A (zh) | 2022-01-07 |
| AU2025267367A1 (en) | 2025-12-04 |
| JP2025081338A (ja) | 2025-05-27 |
| US20220168258A1 (en) | 2022-06-02 |
| MX2021010745A (es) | 2021-12-15 |
| WO2020185640A1 (en) | 2020-09-17 |
| CA3132827A1 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102713072B1 (ko) | 두경부암 치료를 위한 egfr 저해제 | |
| Monnet et al. | Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC) | |
| RU2662298C2 (ru) | Лечение рака комбинацией плинабулина и таксана | |
| JP2009102408A (ja) | ホモハリングトニンを単独で、または他の薬剤と組み合わせて用いる、sti571に耐性または不耐性の慢性骨髄性白血病の治療 | |
| BR112019026486A2 (pt) | tinostamustina para uso no tratamento de câncer de ovário | |
| BR112019026474A2 (pt) | compostos para tratar tnbc | |
| CN111867678A (zh) | 治疗黑色素瘤的方法 | |
| AU2015317856B2 (en) | Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers | |
| US20220241294A1 (en) | Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer | |
| WO2025137692A1 (en) | Combination of dimesna and pemetrexed to treat non-small cell lung cancer (nsclc) | |
| CA3134156C (en) | Chiauranib for treatment of small cell lung cancer | |
| JP6802598B1 (ja) | 抗がん剤の効果増強剤 | |
| US20220168258A1 (en) | Method for treating female non-smokers with non-small cell lung cancer | |
| EP2560648A2 (en) | Method for treating pancreatic cancer | |
| BR112020016073A2 (pt) | Métodos e terapia de combinação para tratar câncer do trato biliar | |
| TW202337897A (zh) | 抗pd-1抗體和抗vegf-a抗體的藥物組合及其使用方法 | |
| de la Vega et al. | Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial | |
| Gent et al. | An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin | |
| Wachters et al. | Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC | |
| JP2013510126A (ja) | コリン含有医薬組成物 | |
| CN118354772A (zh) | 治疗头颈癌的方法 | |
| TW202339753A (zh) | 用於與抗癌藥物共同投與之包含酞嗪酮衍生物之醫藥組合物 | |
| WO2024022282A1 (zh) | 吡啶胺化合物在特定ros1基因融合的非小细胞肺癌中的应用 | |
| TW202506120A (zh) | Bet抑制劑及parp抑制劑於治療胰臟癌之用途 | |
| WO2021219137A1 (zh) | 用于治疗met基因异常疾病的氨基吡啶衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |